Methyl-CpG-Binding Domain Sequencing: MBD-seq
Methyl-CpG-Binding Domain Sequencing: MBD-seq
复制标题
DOI：
10.1007/978-1-4939-7481-8_10
复制
发表时间：
2018-01-01
期刊：
影响因子：
--
通讯作者：
van den Oord, Edwin J. C. G.
中科院分区：
文献类型：
--
作者：
Aberg, Karolina A.;Chan, Robin F.;van den Oord, Edwin J. C. G.
关于甲基化组的潜在重要性的详细生物学知识对于常见疾病通常是缺乏的。因此，全甲基化关联研究（MWAS）对于检测疾病相关甲基化位点至关重要。甲基-CpG结合结构域测序（MBD-seq）与基于抗体的富集相比具有潜在优势，但性能关键取决于使用最佳方案。使用优化的方案，MBD-seq可以近似于全基因组亚硫酸氢盐测序获得的灵敏度/特异性，但成本和时间仅为完成项目的一小部分。因此，MBD-seq在CpG甲基化组提供了全面的第一遍，并且对于MWAS所需的样本量在经济上是可行的。
Detailed biological knowledge about the potential importance of the methylome is typically lacking for common diseases. Therefore, methylome-wide association studies (MWAS) are critical to detect disease relevant methylation sites. Methyl-CpG-binding domain sequencing (MBD-seq) offers potential advantages compared to antibody-based enrichment, but performance depends critically on using an optimal protocol. Using an optimized protocol, MBD-seq can approximate the sensitivity/specificity obtained with whole-genome bisulfite sequencing, but at a fraction of the costs and time to complete the project. Thus, MBD-seq offers a comprehensive first pass at the CpG methylome and is economically feasible with the samples sizes required for MWAS.